The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+
Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs
Getty Images

Markets

Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs

Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals

Synopsis

Sun Pharma is the only Indian company to have made some inroads into speciality drugs. But high investments and uncertainties over ramp up in revenue make investors worried. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off.

Call it a blessing in disguise for the Indian pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis. The Nifty Pharma index has doubled from its lows in March 2020. But the narrative is different for Sun Pharmaceutical Industries, India’s largest pharma company. The company has underperformed its peers such as Dr. Reddy’s Laboratories, Cipla, and Aurobindo Pharma as well as the
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times